TEKI yields 2000000.00% · PFE yields 6.13%● Live data
📍 TEKI pulled ahead of the other in Year 1
Combined, TEKI + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TEKI + PFE for your $10,000?
Tek Digitel Corp. develops equipment that converts analog voice data to a digital format suitable for network transmission using standard Internet Protocols (IP). Its equipment, known as gateway, consists of proprietary computer hardware and software that connects a standard telephone to the Internet or other digital network. The company's Voice over IP (VoIP) technology allows users to transmit all of their voice and fax communications using the Internet, instead of the conventional telephone network. Tek Digitel Corp. focuses on developing customer premise equipment located at the home or office. It targets its products to telecommunications companies that base their telecommunications structure on the Internet by offering Internet connectivity and VoIP as their primary solutions. The company's VoIP gateway devices and V-Server® product line offers services, including local and long-distance voice connectivity; voice features, such as voice mail, unified messaging, and fax transmission, as well as basic Internet data access for multiple users at a single site. The V-Server products are designed for use with a variety of Internet access services, including Integrated Services Digital Networks, Wireless telephones, Digital Subscriber Loops, and Cable modem delivery. The company has also developed personal computer client and server-based provision/management tools to allow the gateway devices to be configured and managed to support the interconnection of users across public Internet or private corporate intranets. The company was formerly known as ATC Group L.L.C. and changed its name to Tek Digitel Corp. in July, 1998. The company is based in Germantown, Maryland.
Full TEKI Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.